The Small Molecule Screening and Synthesis Facility (SMSSF) fosters collaborative drug discovery research between chemists, biologists and physician scientists that leads to the identification of new small molecules that inhibit cancer phenotypes in cellular or animal models and that can be further developed for clinical evaluation in human cancer patients.
Our drug discovery services include:
News and Accomplisments
Two new Specialized Libraries are now available:
Image-based assays on the EVOS® FL Auto Cell Imaging System in 96-well or 384-well plates.
Pharma-experienced consulting on projects and grant applications by Dr. John Gleason, VP Medicinal Chemistry, GlaxoSmithKline (retired).
View SMSSF Scientific Accomplishments.
Funding received from the UWCCC Cancer Center Support Grant (CCSG) for published research, including the use of UWCCC Shared Resources to generate or analyze data, or conduct clinical trials, needs to reference the UWCCC. See Acknowledging UWCCC in Publications, Posters and Presentations.
View the UW Drug Discovery and Development website for more information on other UW-Madison laboratory facilities that provide state-of-the-art instrumentation and expert scientific staff.